Active Surveillance for Cancer of the Prostate (ASCaP)
- Conditions
- Prostate Cancer
- Interventions
- Other: Active surveillance
- Registration Number
- NCT00949819
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Brief Summary
Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.
- Detailed Description
This protocol is not designed as a formal clinical trial, but rather an observational protocol; no treatments and no randomization are included. Longitudinally, specimens and clinical data will be collected to provide information on the following:
* Imaging studies of the prostate
* Rates of curative intervention
* Measures of tumor recurrence/progression
* Disease specific survival
* Overall survival
* Clinical data to track Quality of Life
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 462
- Histologically confirmed adenocarcinoma of the prostate.
- Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
- No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
- Patient has elected Active Surveillance as preferred management plan for prostate cancer.
- Patient consent has been obtained according to local Institutional Review Board .
- Patient is accessible and compliant for follow-up.
- Unwillingness or inability to undergo serial prostate biopsy.
- Overall life expectancy less than 2 years
- Advanced prostate cancer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description no treatment Active surveillance Men with previously untreated, early stage prostate cancer.
- Primary Outcome Measures
Name Time Method Discover and confirm clinical parameters that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables. Interim data analysis will be made every year
- Secondary Outcome Measures
Name Time Method Determine the clinical predictors of disease progression. Measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. Determine factors that lead to active intervention Interim data analysis will be done each year
Trial Locations
- Locations (1)
University of California Los Angeles
🇺🇸Los Angeles, California, United States